药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Rifapentine
Bezitramide
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Bezitramide.
Rifapentine
Ramosetron
The risk or severity of constipation can be increased when Fesoterodine is combined with Ramosetron.
Rifapentine
Eluxadoline
The risk or severity of constipation can be increased when Fesoterodine is combined with Eluxadoline.
Rifapentine
Troleandomycin
The metabolism of Fesoterodine can be decreased when combined with Troleandomycin.
Rifapentine
Danoprevir
The metabolism of Fesoterodine can be decreased when combined with Danoprevir.
Rifapentine
Ribociclib
The metabolism of Fesoterodine can be decreased when combined with Ribociclib.
Rifapentine
Stiripentol
The metabolism of Fesoterodine can be decreased when combined with Stiripentol.
Rifapentine
Elvitegravir
The metabolism of Fesoterodine can be decreased when combined with Elvitegravir.
Rifapentine
Cobicistat
The metabolism of Fesoterodine can be decreased when combined with Cobicistat.
Rifapentine
Boceprevir
The metabolism of Fesoterodine can be decreased when combined with Boceprevir.
Rifapentine
Ditiocarb
The metabolism of Fesoterodine can be decreased when combined with Ditiocarb.
Rifapentine
Midostaurin
The metabolism of Fesoterodine can be decreased when combined with Midostaurin.
Rifapentine
Umeclidinium
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Umeclidinium.
Rifapentine
Secretin porcine
The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Fesoterodine.
Rifapentine
Pramlintide
The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Fesoterodine.
Rifapentine
Mirabegron
The risk or severity of urinary retention can be increased when Fesoterodine is combined with Mirabegron.
Rifapentine
Mianserin
Mianserin may increase the anticholinergic activities of Fesoterodine.
Rifapentine
Aclidinium
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Aclidinium.
Zopiclone
Tucatinib
Tucatinib may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.
Zopiclone
Nintedanib
The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Nintedanib.